Fuji Pharma Co.,Ltd. Logo

Fuji Pharma Co.,Ltd.

Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.

4554 | T

Overview

Corporate Details

ISIN(s):
JP3816200004
LEI:
Country:
Japan
Address:
千代田区三番町5番地7
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fuji Pharma Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products for medical use. The company specializes in hormone medicines, particularly for obstetrics and gynecology, and injectable drugs. Its portfolio also includes internal drugs, external use medications, and diagnostic products. In addition to its proprietary products, Fuji Pharma offers a wide range of contract manufacturing services for various formulations, including solids, injections, ointments, creams, and liquids. The company is noted for its extensive experience and specialized quality containment technology in the production of hormone-based pharmaceuticals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-09 04:10
Registration Form
確認書
Japanese 8.7 KB
2025-05-09 04:09
Interim Report
半期報告書-第61期(2024/10/01-2025/09/30)
Japanese 216.6 KB
2024-12-23 04:46
Post-Annual General Meeting Information
臨時報告書
Japanese 25.0 KB
2024-12-23 04:37
Registration Form
確認書
Japanese 8.7 KB
2024-12-23 04:33
Governance Information
内部統制報告書-第60期(2023/10/01-2024/09/30)
Japanese 23.3 KB
2024-12-23 04:32
Registration Form
有価証券報告書-第60期(2023/10/01-2024/09/30)
Japanese 1.7 MB
2024-07-18 09:11
Registration Form
有価証券届出書(参照方式)
Japanese 285.7 KB
2024-05-10 07:27
Quarterly Report
四半期報告書-第60期第2四半期(2024/01/01-2024/03/31)
Japanese 216.0 KB
2024-05-10 07:27
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-02-09 08:20
Report Publication Announcement
確認書
Japanese 8.7 KB
2024-02-09 08:19
Quarterly Report
四半期報告書-第60期第1四半期(2023/10/01-2023/12/31)
Japanese 178.7 KB
2023-12-21 07:28
Post-Annual General Meeting Information
臨時報告書
Japanese 27.9 KB
2023-12-21 07:26
Registration Form
確認書
Japanese 8.7 KB
2023-12-21 07:25
Governance Information
内部統制報告書-第59期(2022/10/01-2023/09/30)
Japanese 23.3 KB
2023-12-21 07:23
Annual Report
有価証券報告書-第59期(2022/10/01-2023/09/30)
Japanese 1.6 MB

Automate Your Workflow. Get a real-time feed of all Fuji Pharma Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fuji Pharma Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fuji Pharma Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF
Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE

Talk to a Data Expert

Have a question? We'll get back to you promptly.